Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
… And China’s Innovent
by Michael McCoy
March 30, 2015
| A version of this story appeared in
Volume 93, Issue 13
Eli Lilly & Co. and China’s Innovent Biologics are joining in what Lilly calls one of China’s largest cross-border biotech drug development collaborations to date. Innovent was cofounded in 2011 by CEO Michael Yu to develop biologic drugs. Under the deal Innovent will receive $56 million up front and potentially more than $400 million later. The partners will develop at least three cancer treatments—one from Lilly and two from Innovent—over the next decade.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter